SYK and COVID-19: In conjunction with additional emerging evidence indicating the beneficial effect of another SYK inhibitor fostamatinib, our work provides evidence for pursuing clinical trials to investigate repurposing entospletinib for counteracting COVID-19 pathology in severely ill patients.